Literature DB >> 15706029

New approaches to the diagnosis of heparin-induced thrombocytopenia.

Theodore E Warkentin1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome that is most reliably diagnosed when a patient with a clinical scenario that is consistent with heparin-induced immunization is shown to have antiplatelet factor 4/heparin, platelet-activating IgG antibodies. A Bayesian diagnostic approach is discussed, wherein the physician estimates the pretest probability of HIT (eg, the timing and severity of thrombocytopenia in relation to heparin treatment and associated thrombosis) and determines the posttest probability using the results of HIT antibody testing. By this approach, the magnitude of a positive test result determines its likelihood ratio in influencing the posttest probability of HIT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706029     DOI: 10.1378/chest.127.2_suppl.35S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer.

Authors:  Christos Perisanidis; Martina Mittlböck; Alexandra Schoppmann; Gabriela Kornek; Patrick Starlinger; Anton Stift; Edgar Selzer; Christian Schopper; Rolf Ewers
Journal:  Clin Oral Investig       Date:  2012-05-29       Impact factor: 3.573

Review 2.  [Heparin-induced thrombocytopenia].

Authors:  K Gürtler; I Euchner-Wamser; G Neeser
Journal:  Anaesthesist       Date:  2006-09       Impact factor: 1.041

3.  Heparin-induced thrombocytopenia suspected because of repeated hemofiltration filter clotting.

Authors:  Sigismond Lasocki; Nadine Ajzenberg; Hervé Quintard; Gaetan Plantefève; Jean-Marie Desmonts; Philippe Montravers
Journal:  Intensive Care Med       Date:  2007-05-05       Impact factor: 17.440

4.  Heparin-induced thrombocytopenia: overview and treatment.

Authors:  Daniel A Zinkovsky; Marilena S Antonopoulos
Journal:  P T       Date:  2008-11

Review 5.  Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature.

Authors:  Uri Pollak; Joanne Yacobobich; Hannah Tamary; Ovdi Dagan; Orit Manor-Shulman
Journal:  J Extra Corpor Technol       Date:  2011-03

Review 6.  [Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].

Authors:  R Riedel; A Schmieder; A Koster; S Kim; G Baumgarten; J C Schewe
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-12-22       Impact factor: 0.840

7.  Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Robert Giugliano; Christopher B Granger; Kenneth W Mahaffey; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa-Filho; Marcia M Barbosa; Maria da Consolacao V Moreira; Renato A K Kalil; Marildes Freitas; Joao Carlos de Campos Guerra; Marcio Vinicius Lins Barros; Thiago da Rocha Rodrigues; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

8.  Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.

Authors:  Jovan Perunicic; Nebojsa M Antonijevic; Predrag Miljic; Valentina Djordjevic; Danijela Mikovic; Mirjana Kovac; Milan Djokic; Igor Mrdovic; Aleksandra Nikolic; Zorana Vasiljevic
Journal:  J Thromb Thrombolysis       Date:  2007-09-09       Impact factor: 2.300

9.  Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Authors:  Laura Elizabeth Happe; Eileen Marie Farrelly; Richard H Stanford; Matt William Sarnes
Journal:  J Thromb Thrombolysis       Date:  2007-11-24       Impact factor: 2.300

10.  Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis.

Authors:  Amanda R Patrick; Wolfgang C Winkelmayer; Jerry Avorn; Michael A Fischer
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.